Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
AIMS: Ferroportin (FPN) is an iron exporter that plays an important role in cellular and systemic iron metabolism. Our previous work has demonstrated that FPN is decreased in prostate tumors. We sought to identify the molecular pathways regulated by FPN in prostate cancer cells. RESULTS: We show that overexpression of FPN induces profound effects in cells representative of multiple histological subtypes of prostate cancer by activating different but converging pathways. Induction of FPN induces autophagy and activates the transcription factors tumor protein 53 (p53) and Kruppel-like factor 6 (KLF6) and their common downstream target, cyclin-dependent kinase inhibitor 1A (p21). FPN also induces cell cycle arrest and stress-induced DNA-damage genes. Effects of FPN are attributable to its effects on intracellular iron and can be reproduced with iron chelators. Importantly, expression of FPN not only inhibits proliferation of all prostate cancer cells studied but also reduces growth of tumors derived from castrate-resistant adenocarcinoma C4-2 cells in vivo. INNOVATION: We use a novel model of FPN expression to interrogate molecular pathways triggered by iron depletion in prostate cancer cells. Since prostate cancer encompasses different subtypes with a highly variable clinical course, we further explore how histopathological subtype influences the response to iron depletion. We demonstrate that prostate cancer cells that derive from different histopathological subtypes activate converging pathways in response to FPN-mediated iron depletion. Activation of these pathways is sufficient to significantly reduce the growth of treatment-refractory C4-2 prostate tumors in vivo. CONCLUSIONS: Our results may explain why FPN is dramatically suppressed in cancer cells, and they suggest that FPN agonists may be beneficial in the treatment of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the use and interpretation of assays for monitoring autophagy
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy · doi:10.4161/auto.19496 · Cited by 4,330
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712 · cited 2×
“To explore mechanisms of FPN-mediated induction of p21 in PC3 p53 null cells, we analyzed known transcriptional regulators of p21 (1).”
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · cited 7×
“Thus, SASP may represent a bridge between induction of DNA damage, autophagy, and ER stress in cells that overexpress FPN.”
InfluentialKimura, S., Noda, T., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4451 · Cited by 2,278
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 1×
“Further, since DNA damage induces p53 (44, 63) as well as KLF6 (5), DNA damage may also underlie the induction of p53 (Fig.”
Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy
Mancias, J. D., Wang, X., Gygi, S. P., Harper, J. W., & Kimmelman, A. C. (2014) · Nature · doi:10.1038/nature13148 · Cited by 2,084 · cited 2×
“Increasing evidence indicates that autophagy contributes to maintenance of iron balance by promoting the turnover of iron storage proteins (19, 43).”
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 1×
“It includes survival factors, cytokines, and growth factors (3, 72, 76, 78).”
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621 · cited 3×
“Apart from its expression in tissues that regulate systemic iron balance, FPN is also expressed in peripheral tissues and is markedly reduced in a number of tumors (70).”
InfluentialSelf-citationCellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
Dowdle, W. E., Nyfeler, B., Nagel, J., Elling, R. A., Liu, S., Triantafellow, E., Menon, S., Wang, Z., Honda, A., Pardee, G., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3053 · Cited by 759
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541 · cited 1×
“2), as well as ER stress (18, 60).”
The role of iron in cell cycle progression and the proliferation of neoplastic cells
Le, N. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00068-9 · Cited by 453 · cited 1×
“This includes induction of p53 (41), induction of p21 (41), induction of GADD genes (61), induction of autophagy (54), and inhibition of proliferation (38), all of which have been observed in cells treated with iron chelators.”
Meyron‐Holtz, E. G., Ghosh, M. C., Iwai, K., LaVaute, T., Brazzolotto, X., Berger, U. V., Land, W., Ollivierre‐Wilson, H., Grinberg, A., Love, P., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600041 · Cited by 408
Ferroportin-mediated iron transport: Expression and regulation
Ward, D. M., & Kaplan, J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.03.004 · Cited by 373 · cited 2×
“FPN is a cell surface iron efflux pump that is expressed in a variety of tissues (23, 75).”
The p53 response to DNA damage
Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329
Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells
Asano, T., Komatsu, M., Yamaguchi-Iwai, Y., Ishikawa, F., Mizushima, N., & Iwai, K. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01437-10 · Cited by 265 · cited 1×
“Supporting earlier studies (4, 32), recent work has identified a specific cargo receptor for degradation of the iron storage protein ferritin in the autophagolysosome, and suggested that autophagy is S2 for details of other differentially expressed pathways.”
Release of iron from ferritin requires lysosomal activity
Kidane, T. Z., Sauble, E., & Linder, M. C. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00505.2005 · Cited by 263 · cited 1×
“Supporting earlier studies (4,32), recent work has identified a specific cargo receptor for degradation of the iron storage protein ferritin in the autophagolysosome, and suggested that autophagy is important for recycling of intracellular iron (19,43).”
Synthetic and natural iron chelators: Therapeutic potential and clinical use
Hatcher, H. C., Singh, R. N., Torti, F. M., & Torti, S. V. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.121 · Cited by 242
Young, A. R. J., & Narita, M. (2009) · The EMBO Reports · doi:10.1038/embor.2009.22 · Cited by 214 · cited 1×
“It includes survival factors, cytokines, and growth factors (3,72,76,78).”
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212 · cited 2×
“To accomplish this, we used FPN-A77D, a well-characterized FPN mutant with impaired iron efflux function (40,62).”
Hepcidin regulation in prostate and its disruption in prostate cancer
Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., Deng, Z., Blanchette, N., Arvedson, T., Miranti, C. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2465 · Cited by 186
Self-citationRoss, S. L., Tran, L., Winters, A., Lee, K.-J., Plewa, C., Foltz, I., King, C., Miranda, L. P., Allen, J., Beckman, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.017 · Cited by 145 · cited 1×
“Antibodies used were Ab-FPN 38C8 (Amgen) (58) and Alexa Fluor (cid:4) 488 AffiniPure Goat Anti-Human IgG (Catalog No. 109-545-098; Jackson ImmunoResearch Laboratories, West Grove, PA).”
Research works printed but not linked: 57
- 10.1016/j.febslet.2006.10.077 · DOI
- 10.1021/acs.jcim.6b00450 · DOI
- 10.1158/0008-5472.CAN-03-2818 · DOI · Paper page
- 10.1016/j.cmet.2013.06.019 · DOI · Paper page
- 10.1038/nrc3711 · DOI · Paper page
- 10.1586/17474086.2016.1124757 · DOI · Paper page
- 10.3322/canjclin.39.6.376 · doi:10.3322/canjclin.39.6.376
- 10.1002/pros.2990230206 · DOI · Paper page
- 10.1007/s002400000111 · DOI
- Darnell G, 1999, Blood, 94, 781, 10.1182/blood.V94.2.781 · DOI · Paper page
- 10.1371/journal.pone.0036739 · DOI
- 10.1038/onc.2009.231 · DOI
- 10.1016/j.drup.2008.11.001 · DOI
- 10.1146/annurev.nutr.20.1.627 · DOI · Paper page
- 10.1111/j.1749-6632.1992.tb38657.x · DOI · Paper page
- 10.1128/MCB.9.10.4196 · DOI · Paper page
- 10.1016/j.cmet.2005.02.005 · DOI · Paper page
- 10.4161/auto.29394 · DOI · Paper page
- 10.1074/jbc.M114.599480 · DOI
- 10.1016/j.molcel.2008.03.003 · DOI · Paper page
- Hotte SJ, 2010, Curr Oncol, 17, S72, 10.3747/co.v17i0.718 · DOI · Paper page
- 10.1146/annurev.pharmtox.39.1.295 · DOI · Paper page
- 10.1016/j.bbamcr.2016.01.026 · DOI
- Kastan MB, 1991, Cancer Res, 51, 6304
- Koivisto P, 1998, Am J Pathol, 152, 1
- Kuo LJ, 2008, In Vivo, 22, 305
- 10.1016/j.bbcan.2014.01.005 · DOI
- Le NT, 2002, Biochim Biophys Acta, 1603, 31
- 10.1038/sj.leu.2402477 · DOI
- 10.1016/j.bcmd.2005.04.005 · DOI
- 10.18632/oncotarget.4349 · DOI · Paper page
- 10.1074/jbc.M301107200 · DOI · Paper page
- 10.1016/j.cell.2010.01.028 · DOI · Paper page
- 10.1016/j.cell.2006.01.040 · DOI · Paper page
- 10.1038/embor.2008.238 · DOI · Paper page
- 10.1126/science.1066326 · DOI · Paper page
- 10.1016/B978-0-12-385114-7.00004-0 · DOI · Paper page
- 10.1515/BC.2002.051 · DOI · Paper page
- 10.1016/j.bcmd.2003.08.003 · DOI · Paper page
- 10.1126/scitranslmed.3001127 · DOI · Paper page
- 10.1016/j.leukres.2014.06.005 · DOI
- 10.1080/15548627.2015.1091141 · DOI · Paper page
- 10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L · DOI · Paper page
- 10.1210/en.2004-0173 · DOI · Paper page
- 10.1074/jbc.M111.273060 · DOI
- 10.3322/caac.21332 · DOI · Paper page
- 10.1097/01.ju.0000141580.30910.57 · DOI · Paper page
- 10.1136/gut.2005.069021 · DOI
- 10.1002/pros.21383 · DOI · Paper page
- 10.1002/hep.24413 · DOI
- 10.1016/j.bbrc.2011.03.077 · DOI
- 10.1016/j.cell.2010.05.014 · DOI
- 10.1158/0008-5472.CAN-13-1224 · DOI · Paper page
- 10.1158/0008-5472.CAN-15-0563 · DOI · Paper page
- 10.1158/1541-7786.MCR-11-0065 · DOI
- 10.3892/ol.2015.3363 · DOI
- 10.1039/C5MB00663E · DOI · Paper page
Cited by
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels
Trujillo-Alonso, V., Pratt, E. C., Zong, H., Lara-Martinez, A., Kaittanis, C., Rabie, M. O., Longo, V., Becker, M. W., Roboz, G. J., Grimm, J., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0406-1 · Cited by 319
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153
Self-citationThe Role of Iron in Cancer Progression
Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778492 · Cited by 150
Metadata
- Authors
- Deng, Z., Manz, D. H., Torti, S. V., & Torti, F. M.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2019-03-10
- Volume
- 30
- Issue
- 8
- Pages
- 1043-1061
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2765244393
- Cited by
- 47
- References
- 23
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.